계명대학교 의학도서관 Repository

Vaginal compared with intramuscular progestogen for preventing preterm birth in high-risk pregnant women (VICTORIA study): a multicentre, open-label randomised trial and meta-analysis

Metadata Downloads
Author(s)
S‐J ChoiDW KwakK KilS‐C KimJ‐Y KwonYH KimS NaJ‐G BaeH‐H ChaJ‐Y ShimKY OhKA LeeSM KimIA ChoSM LeeGJ ChoYS JoGY ChoiSK ChoiSE HurHS HwangYJ Kim
Keimyung Author(s)
Bae, Jin Gon
Department
Dept. of Obstetrics & Gynecology (산부인과학)
Journal Title
BJOG : an international journal of obstetrics and gynaecology
Issued Date
2020
Volume
127
Issue
13
Keyword
Preterm birthpreventionprogestogenshort cervical length
Abstract
Objective:
To compare the efficacy of two types of progestogen therapy for preventing preterm birth (PTB) and to review the relevant literature.

Design:
A multicentre, randomised, open‐label, equivalence trial and a meta‐analysis.

Setting:
Tertiary referral hospitals in South Korea.

Population:
Pregnant women with a history of spontaneous PTB or short cervical length (<25 mm).

Methods:
Eligible women were screened and randomised at 16‒22 weeks of gestation to receive either 200 mg of vaginal micronised progesterone daily (vaginal group) or an intramuscular injection of 250 mg 17α‐hydroxyprogesterone caproate weekly (IM group). Stratified randomisation was carried out according to participating centres and indications for progestogen therapy. This trial was registered at ClinicalTrials.gov (NCT02304237).

Main outcome measure:
Preterm birth (PTB) before 37 weeks of gestation.

Results:
A total of 266 women were randomly assigned and a total of 247 women (119 and 128 women in the vaginal and IM groups, respectively) were available for the intention‐to‐treat analysis. Risks of PTB before 37 weeks of gestation did not significantly differ between the two groups (22.7 versus 25.8%, P = 0.571). The difference in PTB risk between the two groups was 3.1% (95% CI −7.6 to 13.8%), which was within the equivalence margin of 15%. The meta‐analysis results showed no significant differences in the risk of PTB between the vaginal and IM progestogen treatments.

Conclusion:
Compared with vaginal progesterone, treatment with intramuscular progestin might increase the risk of PTB before 37 weeks of gestation by as much as 13.8%, or reduce the risk by as much as 7.6%, in women with a history of spontaneous PTB or with short cervical length.

Tweetable abstract:
Vaginal and intramuscular progestogen showed equivalent efficacy for preventing preterm birth before 37 weeks of gestation.
Keimyung Author(s)(Kor)
배진곤
Publisher
School of Medicine (의과대학)
Citation
S‐J Choi et al. (2020). Vaginal compared with intramuscular progestogen for preventing preterm birth in high-risk pregnant women (VICTORIA study): a multicentre, open-label randomised trial and meta-analysis. BJOG : an international journal of obstetrics and gynaecology, 127(13), 1646–1654. doi: 10.1111/1471-0528.16365
Type
Article
ISSN
1471-0528
Source
https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.16365
DOI
10.1111/1471-0528.16365
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/42969
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Obstetrics & Gynecology (산부인과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.